PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), a healthcare company and developer of the Microcyn® Technology, today provided an update on its key product and commercial activities in anticipation of its participation at the Financial West Investor Conference in Portland, Oregon on Thursday. The company’s lead compound, Microcyn® Technology, mimics aspects of the human immune system, and is formulated as safe as saline and reduces the overall use of antibiotics. The Microcyn Technology has been formulated for numerous products, each with distinct potency and safety for a wide range of indications. Each product has its own specific regulatory claims depending on country, regulatory requirements and are further supported by scientific studies and trials where applicable.
